A comparison study on efficacy, insulin sensitivity and safety of glimepiride/metformin fixed dose combination vs glimepiride single therapy on type 2 diabetes mellitus patients with basal insulin therapy
Diabetes Research and Clinical Practice Jul 24, 2019
Yu HM, et al. - Researchers conducted this randomized, open-label, parallel, 16-week trial to investigate the effectiveness, insulin sensitivity, and safety of administering sulfonylurea-based drugs and metformin combined with basal insulin. For this investigation, 97 type 2 diabetic patients were chosen and randomized into an insulin glargine plus fixed-dose combination glimepiride 1 mg and metformin 500 mg twice daily group (the G/M group) and an insulin glargine plus glimepiride 4 mg once daily group (the G group). A significantly larger reduction in HbA1c and 2-hour post prandial glucose was seen with the G/M group vs the G group. Both therapies are relatively safe but the G/M group was more effective in lowering blood glucose levels.
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty
-
Paid Market Research Surveys
-
Case discussions, News & Journals' summaries